Enovis (NYSE:ENOV) and Azenta (NASDAQ:AZTA) Head-To-Head Comparison

Azenta (NASDAQ:AZTA) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Azenta and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Azenta	-10.01%	1.40%	1.17%
Enovis	-61.22%	7.79%	4.00%

Valuation and Earnings

This table compares Azenta and Enovis”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$593.82 million	3.01	-$55.76 million	($1.30)	-29.91
Enovis	$2.11 billion	0.60	-$825.49 million	($23.66)	-0.93

Azenta has higher earnings, but lower revenue than Enovis. Azenta is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

99.1% of Azenta shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 10.9% of Azenta shares are held by insiders. Comparatively, 2.7% of Enovis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Azenta has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Azenta and Enovis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1	3	4	0	2.38
Enovis	1	0	7	0	2.75

Azenta presently has a consensus price target of $41.83, indicating a potential upside of 7.60%. Enovis has a consensus price target of $46.71, indicating a potential upside of 112.35%. Given Enovis’ stronger consensus rating and higher probable upside, analysts plainly believe Enovis is more favorable than Azenta.

Summary

Enovis beats Azenta on 8 of the 14 factors compared between the two stocks.

About Azenta

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.